TABLE 1.

Prevalence at baseline and incidence of resistance-associated mutations within the HBV polymerase during 3TC treatment as determined by direct sequencing of PCR products

Mutation within HBV polymerase (rt)Cumulative incidence rate during 3TC treatment (%) [no. with HBV genotype A/no. with HBV genotype D]
At baseline (n = 96)After 1 yr (n = 96)After 2 yr (n = 92)
L180M0 (0)10 (10) [8/2]26 (28) [19/7]
M204I (YIDD)0 (0)5 (5) [2/3]15 (16) [5/10]
M204V (YVDD)0 (0)14 (14) [14/0]26 (28) [21/5]
V207I1 (1)a0 (0)b1 (1) [1/0]
  • a This patient (case patient) carried HBV genotype A.

  • b The patient with an rtV207I mutation at baseline (case patient) was excluded.